CIK 0000818033 · Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 942875566
- Phone
- 8582514400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-13 | Quart Barry D Chief Executive Officer | Option exercise · Restricted Stock Units | −3,645 | 25,521 | ||
| 2023-01-13 | Quart Barry D Chief Executive Officer | Option exercise · Restricted Stock Units | −16,122 | 114,807 | ||
| 2023-01-13 | POYHONEN JOHN President & CCO | Option exercise | +1,250 | 40,294 | ||
| 2023-01-13 | POYHONEN JOHN President & CCO | Option exercise | +4,564 | 44,858 | ||
| 2023-01-13 | POYHONEN JOHN President & CCO | Shares withheld for taxes | −2,012 | $3.17 | $6K | 42,846 |
| 2023-01-13 | POYHONEN JOHN President & CCO | Option exercise · Restricted Stock Units | −1,250 | 8,750 | ||
| 2023-01-13 | POYHONEN JOHN President & CCO | Option exercise · Restricted Stock Units | −4,564 | 32,500 | ||
| 2023-01-13 | Peraza Lisa VP, Chief Accounting Officer | Option exercise | +552 | 21,141 | ||
| 2023-01-13 | Peraza Lisa VP, Chief Accounting Officer | Option exercise | +1,933 | 23,074 | ||
| 2023-01-13 | Peraza Lisa VP, Chief Accounting Officer | Shares withheld for taxes | −1,013 | $3.17 | $3K | 22,061 |
| 2023-01-13 | Peraza Lisa VP, Chief Accounting Officer | Option exercise · Restricted Stock Units | −552 | 3,864 | ||
| 2023-01-13 | Peraza Lisa VP, Chief Accounting Officer | Option exercise · Restricted Stock Units | −1,933 | 13,761 | ||
| 2023-01-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise | +1,250 | 21,381 | ||
| 2023-01-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise | +4,564 | 25,945 | ||
| 2023-01-13 | MANHARD KIMBERLY EVP, Drug Development | Shares withheld for taxes | −2,012 | $3.17 | $6K | 23,933 |
| 2023-01-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise · Restricted Stock Units | −1,250 | 8,750 | ||
| 2023-01-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise · Restricted Stock Units | −4,564 | 32,500 | ||
| 2022-12-16 | Christian Waage Director | Grant or award | +38,580 | 52,232 | ||
| 2022-12-16 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +77,160 | 77,160 | ||
| 2022-12-16 | Rodriguez Susan Director | Grant or award | +38,580 | 55,282 |
Page 17 of 28 · 557 trades